Literature DB >> 20429631

No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma.

A Furdova1, P Slezak, M Chorvath, I Waczulikova, M Sramka, G Kralik.   

Abstract

To report the treatment outcome and possible survival difference between radical surgical treatment (enucleation) or stereotactic radiosurgery (SRS). LINAC stereotactic radiosurgery is an alternative treatment for posterior uveal melanoma used in Slovakia since 1999. The study analyzed patients treated for posterior uveal melanoma in the period 2001-2008. The aim of the study was to compare the relapse-free survival in the cohort of patients primarily treated with surgery (enucleation) or SRS. A total number of 84 patients were included, treatment was determined on a case-by-case basis. We reviewed the records of patients with ciliary body or choroidal melanoma treated by enucleation - 44 patients (52%) and SRS - 40 patients (48%). The therapeutic attitude was established on the basis of ophthalmoscopy, ultrasound (A, B mode), other ophthalmological findings, visual acuity, and general status of each patient. Volume of the tumor was calculated using the formula: "pi/6 x length x width x height" for each patient. All of the patients before decision to "conservative" attitude therapy underwent MRI examination. The therapeutic dose in SRS patients group was 35.0-38.0 Gy. The data were analyzed using Kaplan - Meier survival method for the differences in survival rates between the treatment groups, and afterwards by Cox s proportional hazard method with predictors involved. Among the baseline covariates evaluated, only age affected the prognosis for survival to a statistically important, however not significant degree. The risk of death among patients treated with enucleation relative to those treated with stereotaxy after adjustment for baseline characteristics of patients, age, and tumor volumes was not significant [1.82] (95% CI, 0.46 to 7.30; P = 0.396). The overall five-year survival rate for patients with posterior uveal melanoma was 72%. Treatment by either primary enucleation or SRS according to our results does not appear to influence the development of metastases in patients with uveal melanoma; the survival prognosis is essentially determined by the stage and character of the tumor. No survival difference attributable to stereotactic irradiation of uveal melanoma has been demonstrated in this retrospective study. A small difference is possible, but a clinically meaningful difference in mortality rates, whether from all causes or from metastatic melanoma, is unlikely. Treatment by either radical surgical attitude (enucleation) or "conservative" LINAC- SRS does not appear to influence the survival rate in patients with uveal melanoma.

Entities:  

Mesh:

Year:  2010        PMID: 20429631

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  4 in total

1.  Non-invasive detection and complementary diagnosis of liver metastases via chemokine receptor 4 imaging.

Authors:  Hua Yang; Shanshan Tan; Jingjuan Qiao; Yiting Xu; Zongxiang Gui; Yuguang Meng; Bin Dong; Guangda Peng; Oluwatosin Y Ibhagui; Weiping Qian; Jimmy Lu; Zezhong Li; Guimin Wang; Jinping Lai; Lily Yang; Hans E Grossniklaus; Jenny J Yang
Journal:  Cancer Gene Ther       Date:  2022-02-10       Impact factor: 5.854

2.  Early experiences of planning stereotactic radiosurgery using 3D printed models of eyes with uveal melanomas.

Authors:  Alena Furdová; Miron Sramka; Andrej Thurzo; Adriana Furdová
Journal:  Clin Ophthalmol       Date:  2017-01-31

3.  Two 11-Years Periods Statistics and Trends of Enucleation and Evisceration.

Authors:  Alena Furdova; Kristina Horkovicova; Robert Furda; Miron Sramka; Jan Rybar; Pavol Kusenda; Zuzana Pridavkova
Journal:  J Craniofac Surg       Date:  2021 Nov-Dec 01       Impact factor: 1.172

4.  Carbon ion radiotherapy for synchronous choroidal melanoma and lung cancer: A case report.

Authors:  Yan-Shan Zhang; Ting-Chao Hu; Yan-Cheng Ye; Jin-Hua Han; Xiao-Jun Li; Yi-He Zhang; Wei-Zuo Chen; Hong-Yu Chai; Xin Pan; Xin Wang; Yu-Ling Yang
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.